Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CESAMET vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nabilone is a synthetic cannabinoid (CB1 receptor agonist) with antiemetic and anxiolytic effects. It binds to central cannabinoid receptors (CB1) in the brain, inhibiting neurotransmitter release and modulating emetic pathways.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) refractory to conventional antiemetics
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
1-2 mg orally twice daily; maximum 6 mg/day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 35 hours (range 25–50 hours) in adults. Due to prolonged half-life and active metabolites, steady-state may take 5–7 days; accumulation occurs with repeated dosing.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic, primarily via CYP3A4 and CYP2C9; undergoes first-pass metabolism; multiple metabolites including active 11-hydroxy-nabilone
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily hepatic metabolism with biliary excretion. ~65% eliminated in feces as metabolites, ~20% in urine. Less than 1% excreted unchanged.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
90–95% bound to plasma proteins, primarily albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 2.5–5.5 L/kg, indicating extensive tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is approximately 10–20% due to extensive first-pass metabolism.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No specific dosage adjustment recommended based on GFR; use with caution in severe renal impairment.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not approved for use in pediatric patients; safety and efficacy not established.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at 1 mg once daily; titrate slowly due to increased sensitivity to adverse effects.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Central nervous system depression (drowsiness, dizziness, ataxia),Psychiatric effects (euphoria, dysphoria, paranoia, hallucinations),Cognitive and motor impairment (do not drive or operate machinery),Risk of dependence and withdrawal syndrome,Use with caution in patients with history of psychiatric disorders,May increase heart rate and blood pressure
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to nabilone or any cannabinoid,History of seizure disorder,Breastfeeding (excreted in milk)
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Take with food or milk to reduce gastrointestinal upset; avoid grapefruit juice as it may alter drug metabolism.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Nabilone (Cesamet) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects including skeletal anomalies at doses 0.2-2 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may increase risk of congenital malformations. Second and third trimester exposure may affect fetal growth and neurobehavioral development. Potential risks include low birth weight, preterm birth, and neonatal withdrawal symptoms.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Nabilone is excreted into breast milk; a specific M/P ratio is not reported. Due to the high lipid solubility and long half-life, significant infant exposure is expected. Breastfeeding is contraindicated due to potential adverse effects on infant neurodevelopment and cannabinoid receptor activation.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced hepatic metabolism) may reduce nabilone serum concentrations, potentially requiring dose adjustments. However, due to lack of safety data, use during pregnancy is not recommended. If deemed essential, the lowest effective dose should be used, and close monitoring for efficacy and toxicity is advised.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Titrate slowly to reduce risk of syncope and orthostatic hypotension; monitor for dizziness and sedation; may cause euphoria or dysphoria; use with caution in patients with history of psychiatric disorders; taper to discontinue.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Avoid driving or operating machinery until you know how this drug affects you.,Get up slowly from sitting or lying down to prevent dizziness or fainting.,Avoid alcohol and other sedatives while taking this medication.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Store at room temperature away from moisture and heat.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CESAMET vs ABSTRAL, answered by our medical review team.
CESAMET is a Antiemetic (cannabinoid) that works by Nabilone is a synthetic cannabinoid (CB1 receptor agonist) with antiemetic and anxiolytic effects. It binds to central cannabinoid receptors (CB1) in the brain, inhibiting neurotransmitter release and modulating emetic pathways.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CESAMET and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CESAMET is: 1-2 mg orally twice daily; maximum 6 mg/day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CESAMET and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CESAMET is classified as Category C. Nabilone (Cesamet) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects including skeletal anomalies at doses 0.2-2 times the maximum recommende. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.